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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to a 
combination of plant sterols and Cholesternorm®mix and reduction of 
blood LDL-cholesterol concentrations pursuant to Article 14 of Regulation 
(EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Health Concern B.V., submitted for authorisation of a claim pursuant to Article 14 
of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the Panel on Dietetic 
Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a 
health claim related to a combination of plant sterols and Cholesternorm®mix and reduction of blood LDL-
cholesterol concentrations. The food which is the subject of the health claim is a combination of plant sterols 
(free and in esterified form) and Cholesternorm®mix and provides at the levels of the proposed conditions of use 
around 0.52 g plant sterols, 0.95 g linoleic acid, 0.13 g alpha-linolenic acid and 0.13 g pectins per day. The 
combination of plant sterols and Cholesternorm®mix, which is the subject of the claim, is sufficiently 
characterised in relation to the claimed effect. Reduction of blood LDL-cholesterol concentrations is a beneficial 
physiological effect. A reduction in blood LDL-cholesterol concentrations reduces the risk of coronary heart 
disease. The Panel notes that no evidence was provided that plant sterols or constituents other than plant sterols 
in Cholesternorm®mix, which have a role in the claimed effect, could reasonably be expected to have an effect 
on blood LDL-cholesterol concentrations at the proposed conditions of use. The Panel notes that no human 
interventions studies were provided from which conclusions could be drawn for the scientific substantiation of 
the claim. A cause and effect relationship has not been established between the consumption of a combination of 
plant sterols and Cholesternorm®mix and reduction of blood LDL-cholesterol concentrations at the proposed 
conditions of use. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following an application from Health Concern B.V., submitted for authorisation of a claim pursuant 
to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to a combination of plant sterols and 
Cholesternorm®mix and reduction of blood LDL-cholesterol concentrations. 
The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction.  
The food constituent that is the subject of the health claim (originally for Claim Serial No 0314_NL 
and after clarification for Claim Serial No 0239_NL) is “plant sterols in combination with 
Cholesternorm®mix”. The food, which is the subject of the claim, provides, at the levels of the 
proposed conditions of use, around 0.52 g plant sterols, 0.95 g linoleic acid, 0.13 g alpha-linolenic 
acid and 0.13 g pectins per day. The Panel considers that the food constituent, a combination of plant 
sterols (free and in esterified form) and Cholesternorm®mix, which is the subject of the health claim, 
is sufficiently characterised in relation to the claimed effect.  
The claimed effect is “plant sterols together with the Cholestemorm@mix of cholesterol lowering 
ingredients lowers LDL-cholesterol”. The target population proposed by the applicant is individuals 
who wish to reduce their blood cholesterol levels. The Panel considers that reduction of blood LDL-
cholesterol concentrations is a beneficial physiological effect. A reduction in blood LDL-cholesterol 
concentrations reduces the risk of coronary heart disease. 
No information on the literature search strategy used to identify the body of pertinent scientific data 
for the scientific substantiation of the claim has been provided by the applicant. The Panel considers 
that the criteria and process used by the applicant for the identification and selection of data is 
unclear, may be subject to bias, and does not allow an evaluation of whether the totality of the 
scientific evidence, which may be pertinent for the scientific substantiation of the claim, has been 
provided.  
The applicant provided seven published human intervention studies on plant sterols and stanols and 
one unpublished human intervention study (claimed to be proprietary) on plant sterols in combination 
with Cholesternorm®mix on blood cholesterol concentrations for the scientific substantiation of the 
claim. 
In the randomised, double-blind, placebo-controlled parallel study which investigated the effect of the 
combination of plant sterols and Cholesternorm®mix on blood cholesterol concentrations, 54 healthy 
male subjects were randomised to consume daily either intervention or control spreads for six weeks. 
The Panel notes that even though the applicant was requested during the validation period to provide 
the full study report, only a summary report was submitted. The Panel also notes that the composition 
of the control spread, which contained around twice the amount of alpha-linolenic acid and of linoleic 
acid than the intervention spread as well as a comparable amount of fibres, did not allow conclusions 
to be drawn on an effect of the combination of plant sterols and Cholesternorm®mix on blood 
cholesterol concentrations and that there is uncertainty whether the study was properly randomised. 
The Panel also notes that only per protocol analysis was presented, that baseline values and repeated 
measures were not taken into account in the analysis, that a requested re-analysis of data was not 
presented by the applicant and that the set of raw data provided was incomplete. The Panel considers 
that owing to the major methodological limitations of this study no conclusions can be drawn from 
this study for the scientific substantiation of the claim. 
The Panel notes that none of the human intervention studies provided on plant sterols and stanols 
alone investigated dose ranges in line with the proposed conditions of use and considers that these 
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studies do not provide any additional information to the Panel’s previous evaluations of claims on 
plant sterols and stanols and maintenance/reduction of blood LDL-cholesterol concentrations, which 
have been assessed with favourable outcomes. 
The Panel notes that no evidence was provided that plant sterols or constituents other than plant 
sterols in Cholesternorm®mix, which have a role in the claimed effect, could reasonably be expected 
to have an effect on blood LDL-cholesterol concentrations at the proposed conditions of use. 
The Panel notes that no human interventions studies were provided from which conclusions could be 
drawn for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of plant sterols and Cholesternorm®mix and reduction of blood LDL-
cholesterol concentrations at the proposed conditions of use. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The applications were received on 03/02/2009 (Claims Serial No 0239_NL) and on 
14/10/2011 (Claims Serial No 0314_NL). 
 The scope of the applications was proposed to fall under a health claim referring to disease 
risk reduction and the applications include requests for the protection of proprietary data. 
 For Claims Serial No 0239_NL, which was related to a claim on plant sterols and reduction of 
blood cholesterol concentrations, EFSA sent a request for clarification to the Competent 
Authority of the Netherlands on 22/04/2009. 
 On 26/06/2009, the applicant expressed his intention to EFSA to withdraw the application 
Claims Serial No 0239_NL. 
 The Competent Authority of the Netherland informed EFSA on 19/11/2009 that the 
withdrawal of the application Claims Serial No 0239_NL could not be confirmed. 
 On 11/10/2011, EFSA requested the Competent Authority of the Netherlands to clarify the 
status of application Claims Serial No 0239_NL. 
 On 07/11/2011, the Competent Authority of the Netherlands informed EFSA that the 
applicant expressed his wish to proceed with the evaluation of the application Claims Serial 
No 0239_NL. 
 On 04/11/2011 (Claims Serial No 0314_NL) and on 09/11/2011 (Claims Serial No 
0239_NL), during the validation period of the application, EFSA sent a request to the 
applicant to provide missing information. 
 The applicant provided the missing information for Claims Serial No 0239_NL and Claims 
Serial No 0314_NL on 09/02/2012 and requested that the food which is the subject of the 
claim for Claims Serial No 0239_NL to be amended from plant sterols to plant sterols in 
combination with Cholesternorm®mix. 
 The scientific evaluation procedure started on 20/02/2012. 
 During its meeting on 21-23 March 2012, the Working Group on Claims of the NDA Panel 
agreed on a list of questions for the applicant to provide additional information to accompany 
the application, and the clock was stopped on 26/03/2012 in compliance with Article 16(1) of 
Regulation (EC) No 1924/2006. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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 On 06/06/2012, EFSA received the requested information as submitted by the applicant and 
the clock was restarted. 
 During its meeting on 27/06/2012, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to a combination 
of plant sterols and Cholesternorm®mix and reduction of blood LDL-cholesterol 
concentrations. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: a combination of plant sterols and 
Cholesternorm®mix and reduction of blood LDL-cholesterol concentrations. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of a combination of plant sterols and Cholesternorm®mix, a positive assessment of its 
safety, nor a decision on whether a combination of plant sterols and Cholesternorm®mix is, or is not, 
classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework 
of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Health Concern B.V., Randhoeve 225a 3995 GA Houten, the 
Netherlands. 
The applications include requests for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 
Food/constituent as stated by the applicant 
According to the applicant, the food, which is the subject of the claim for Claim Serial No 0314_NL, 
is plant sterols and a mix of ingredients (Cholesternorm®mix) used in fat based product including fat 
spreads and low-fat products. The mix is a combination of ingredients: high oleic sunflower oil, 
omega 6 from sunflower oil, inulin, sunflower lecithin, primrose oil, safflower oil, vitamin A, E, B3, 
B6, folic acid, D3, B12, omega 3 from fish oil, shellac, apple pectin, choline, anti-oxidant: E304, 
E306 and plant sterols. The ratio plant sterols: mix is 1:8.9. For Claim Serial No 0239_NL the initial 
application was made for a claim on plant sterols alone. During the validation of the application, the 
applicant requested that the food which is the subject of the claim for Claims Serial No 0239_NL to 
be amended from plant sterols to plant sterols in combination with Cholesternorm®mix in line with 
Claim Serial No 0314_NL. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect relates to: “Plant sterols together with the 
Cholestemorm®mix of cholesterol lowering ingredients lowers LDL-cholesterol. Not only the plant 
sterols but also the ingredients of the Cholestemorm®mix contribute to the cholesterol lowering 
effect.” 
Wording of the health claim as proposed by the applicant 
The following wording is proposed by the applicant: “Actively lowers cholesterol.” 
Specific conditions of use as proposed by the applicant 
The applicant proposes the target population to be people who want to lower their cholesterol level 
and the quantity to be consumed to be three portions (30 grams) per day of the spread, which is 
corresponding to 0.52 grams of plant sterols and 4.5 grams of Cholestemorm®mix per day.  
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim (originally for Claim Serial No 0314_NL 
and after clarification for Claim Serial No 0239_NL) is plant sterols in combination with 
Cholesternorm®mix. 
Plant sterols are naturally occurring compounds structurally similar to cholesterol. Plant sterols are 
derived from vegetable oil (such as soybean or rape seed oil) or from tall oil sterols (wood sterols). 
Throughout this opinion, quantities of plant sterols are expressed as the equivalent weights of free 
(i.e. un-esterified) plant sterols. 
A combination of plant sterols and Cholesternorm®mix and 
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Cholesternorm®mix is a mixture of different plant oils, fish oil, lecithin, inulin, pectins, choline, 
shellac wax and vitamins, and contains around 21 wt% linoleic acid (LA), 3 wt% alpha-linolenic acid 
(ALA) and 3 wt% pectins. The exact composition of the mixture and the fatty acid profile has been 
provided by the applicant. The food constituent, which is the subject of the claim, provides, at the 
levels of the proposed conditions of use, around 0.52 g plant sterols, 0.95 g LA, 0.13 g ALA and 
0.13 g pectins per day. 
The Panel considers that the food constituent, a combination of plant sterols (free and in esterified 
form) and Cholesternorm®mix, which is the subject of the health claim, is sufficiently characterised 
in relation to the claimed effect.  
2. Relevance of the claimed effect to human health 
The claimed effect is “plant sterols together with the Cholestemorm®mix of cholesterol lowering 
ingredients lowers LDL-cholesterol”. The target population proposed by the applicant is individuals 
who wish to reduce their blood cholesterol levels. 
Coronary heart disease (CHD) is a leading cause of mortality and morbidity in European populations 
with over 1.9 million deaths in the European Union and over 4.35 million deaths in Europe each year 
(Petersen et al., 2005). Elevated blood cholesterol is an important modifiable risk factor in the 
development of CHD (WHO, 2002). 
It has been shown that blood cholesterol can be decreased by drugs, and by dietary and lifestyle 
changes (Denke, 2005; Gordon, 2000; Katan et al., 2003; Law, 2000; Ornish et al., 1998; Pedersen et 
al., 2005; Van Horn et al., 2008). 
The Panel considers that reduction of blood LDL-cholesterol concentrations is a beneficial 
physiological effect. A reduction in blood LDL-cholesterol concentrations reduces the risk of CHD. 
3. Scientific substantiation of the claimed effect 
Claims on plant sterols/stanols in amounts of 0.8 g/day, on LA in amounts of 1.5 g/day, on ALA in 
amounts of 0.3 g/day, and on pectins in amounts of 6 g/day and maintenance/reduction of blood LDL-
cholesterol concentrations have already been assessed by the Panel with favourable outcomes (EFSA, 
2008a, 2008b, 2009a, 2009b; EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 
2009a, 2009b, 2010a, 2010b), while the food constituent, which is the subject of the claim, provides, 
at the levels of the proposed conditions of use, around 0.52 g plant sterols, 0.95 g LA, 0.13 g ALA 
and 0.13 g pectins per day.  
No information on the literature search strategy used to identify the body of pertinent scientific data 
for the scientific substantiation of the claim has been provided by the applicant. Upon request from 
EFSA to specify the search strategy, the applicant provided general information on the strategy for 
selecting the food constituents, which are the subject of the claim, but did not submit any further 
details on the literature search strategy. The Panel considers that the criteria and process used by the 
applicant for the identification and selection of data is unclear, may be subject to bias, and does not 
allow an evaluation of whether the totality of the scientific evidence, which may be pertinent for the 
scientific substantiation of the claim, has been provided.  
The applicant provided seven published human intervention studies on plant sterols and stanols 
(Amundsen et al., 2002; Cleghorn et al., 2003; Hendriks et al., 1999; 2003; Jones et al., 2000; 
Miettinen et al., 1995; Weststrate and Meijer, 1998) and one unpublished human intervention study 
(claimed to be proprietary) on plant sterols in combination with Cholesternorm®mix on blood 
cholesterol concentrations (Beukelman, 2008, unpublished; Gutjahr et al., 2006, unpublished) for the 
scientific substantiation of the claim. 
A combination of plant sterols and Cholesternorm®mix and 
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In the randomised, double-blind, placebo-controlled parallel study which investigated the effect of the 
a combination of plant sterols and Cholesternorm®mix on blood cholesterol concentrations 
(Beukelman, 2008, unpublished; Gutjahr et al., 2006, unpublished), 54 healthy male subjects (mean 
age: 49.7 years) with mean baseline LDL-cholesterol concentrations of 3.35±0.70 mmol/L were 
randomised to consume daily either 30 g of “Double Active” spread, which contained 0.51 g plant 
sterols (0.87 g plant sterol esters) and 4.5 g Cholesternorm®mix (containing i.a. 0.95 g/day LA, 
0.13 g/day ALA and 0.13 g/day pectins) (n=25) or 30 g of a conventional spread (control, n=29) 
divided into three equal portions per day for six weeks. The content of ALA and LA in the control 
spread was around twice the content in the intervention spread and both spreads had a comparable 
amount of fibres.  
Upon request from EFSA to specify the method of randomisation of subjects, the applicant indicated 
that the test products were coded and were randomly assigned to subjects but did not provide any 
further information about the generation of codes or the method of assigning the products to subjects. 
Blood lipids were measured at baseline and weeks three and six. Five subjects were excluded from 
analysis due to sickness or non-compliance (three from the intervention and two from the placebo 
group). Data analysis was carried out on 22 subjects in the intervention and 27 subjects in the control 
group. Results were reported as percent change from baseline without reporting p-values or the 
statistical tests applied, as difference between groups of absolute LDL-cholesterol concentrations at 
week six and of absolute changes from baseline at week six, analysed by the independent Student’s t-
test. Results of an analysis by the Mann Whitney U test for weeks three and six were also reported. 
Data analysis did not take into account baseline values and repeated measures and results of an 
intention-to-treat analysis were not presented. A re-analysis of data, which was requested by EFSA 
during the clock-stop procedure, was not provided by the applicant. Upon request from EFSA to 
present the raw data of the study, the applicant provided an incomplete set of raw data from which 
data of those subjects excluded from analysis were removed. 
The Panel notes that even though the applicant was requested during the validation period to provide 
the full study report, only a summary report was submitted. The Panel also notes that the composition 
of the control spread used in the study did not allow conclusions to be drawn on an effect of the 
combination of plant sterols and Cholesternorm®mix on blood cholesterol concentrations and that 
there is uncertainty whether the study was properly randomised. The Panel also notes that only per 
protocol analysis was presented, that baseline values and repeated measures were not taken into 
account in the analysis, that a requested re-analysis of data was not presented by the applicant and that 
the set of raw data provided was incomplete. The Panel considers that owing to the major 
methodological limitations of this study no conclusions can be drawn from this study for the scientific 
substantiation of the claim. 
The Panel notes that none of the human intervention studies provided on plant sterols and stanols 
alone investigated dose ranges in line with the proposed conditions of use and considers that these 
studies do not provide any additional information to the Panel’s previous evaluations of claims on 
plant sterols and stanols and maintenance/reduction of blood LDL-cholesterol concentrations, which 
have been assessed with favourable outcomes (EFSA, 2008a, 2008b, 2009a, 2009b; EFSA Panel on 
Dietetic Products Nutrition and Allergies (NDA), 2010a). 
The Panel notes that no evidence was provided that plant sterols or constituents other than plant 
sterols in Cholesternorm®mix, which have a role in the claimed effect, could reasonably be expected 
to have an effect on blood LDL-cholesterol concentrations at the proposed conditions of use. 
The Panel notes that no human interventions studies were provided from which conclusions can be 
drawn for the scientific substantiation of the claim. 
A combination of plant sterols and Cholesternorm®mix and 
reduction of blood LDL-cholesterol concentrations 
 
 
10 EFSA Journal 2012;10(7):2810 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of plant sterols and Cholesternorm®mix and reduction of blood LDL-
cholesterol concentrations at the proposed conditions of use. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, a combination of plant sterols (free and in esterified form) and 
Cholesternorm®mix, which is the subject of the claim, is sufficiently characterised in relation 
to the claimed effect.  
 A reduction of blood LDL-cholesterol concentrations is a beneficial physiological effect. A 
reduction in blood LDL-cholesterol concentrations reduces the risk of coronary heart disease.  
 A cause and effect relationship has not been established between the consumption of a 
combination of plant sterols and Cholesternorm®mix and reduction of blood LDL-cholesterol 
concentrations at the proposed conditions of use. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on a combination of plant sterols and Cholesternorm®mix and reduction of 
blood LDL-cholesterol concentrations pursuant to Article 14 of Regulation (EC) No 1924/2006 
(Claim serial No: 0239_NL and 0314_NL). October 2011. Submitted by Health Concern B.V. 
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GLOSSARY AND ABBREVIATIONS 
 
LDL Low density lipoproteins 
CHD Coronary heart disease 
ALA Alpha-linolenic acid 
LA Linoleic acid 
